Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregiver
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
  • Our Products
    • MIPLYFFA®
    • OLPRUVA ®
  • Our Pipeline
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

SEC Filing Details

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • State Compliance
  • SEC Filings
  • Contact
  • Email Alerts
  • FAQs

Document Details

Form
DEF 14A
Filing Date
Apr 3, 2024
Document Date
May 13, 2024
Form Description
Official notification to shareholders of matters to be brought to a vote ("Proxy")
Filing Group
Proxy Filings
Company
Zevra Therapeutics, Inc.
Issuer
ZEVRA THERAPEUTICS, INC.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
XML - XBRL INSTANCE DOCUMENT
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregiver
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
  • Our Products
    • MIPLYFFA®
    • OLPRUVA ®
  • Our Pipeline
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2026 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top